Patients with [[leptomeningeal carcinomatosis]] face a particularly grim prognosis. Current treatment consists of [[intrathecal]] delivery of [[methotrexate]] (MTX) or [[cytosine arabinoside]] (Ara-C) via [[ventricular access device]] ([[Ommaya reservoir]]) or [[lumbar puncture]]. Yet despite these interventions, the median survival after diagnosis is only 4-7 months
((Chen TC, Napolitano GR, Adell F, Schönthal AH, Shachar Y. Development of the
Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note. J 
Neurosurg. 2015 Aug;123(2):362-72. doi: 10.3171/2014.10.JNS14343. Epub 2015 May
8. PubMed PMID: 25955873.
)).